413
Participants
Start Date
February 20, 2019
Primary Completion Date
December 23, 2019
Study Completion Date
July 20, 2020
Adalimumab
Patients in AVT02 arm will receive an initial loading dose of AVT02 80 mg (2 × 40 mg) administered subcutaneously (SC), followed by 40 mg given SC once every other week (EOW) starting 1 week after the loading dose, and will continue to receive AVT02 until Week 48 Patients in EU-Humira arm will receive an initial loading dose of Humira 80 mg (2 × 40 mg) administered SC, followed by 40 mg given SC EOW starting 1 week after the loading dose and will continue to receive Humira until Week 48
Innomedica OU, Tallinn
OU Vahlberg & Pild, Tallinn
North Estonia Medical Centre Foundation, Dermatovenerology Centre, Tallinn
Tartu University Hospital, Dermatology Clinic, Tartu
Aleksandre Aladashvili Clinic LLC, Tbilisi
The first University Clinic of Tbilisi State Medical University, Tbilisi
Scientific Research National Center of Dermatology and Venereology LLC, Tbilisi
Health Institute LLC, Tbilisi
David Abuladze Georgian-Italian Clinic LTD, Tbilisi
ClinicMed Daniluk, Nowak Spółka Jawna, Bialystok
NZOZ Osteo-Medic s.c. Artur Racewicz, Jerzy Supronik, Bialystok
Synexus Polska Sp. z o.o. Oddział w Gdańsku, Gdansk
Center Med Kraków Sp. Z o.o., Krakow
Centrum Medyczna ALL-MED, Lodz
"NZOZ Nasz Lekarz Sławomir Jeka, Praktyka Grupowa Lekarzy Rodzinnych z Przychodnią Specjalistyczną", Torun
Synexus Polska Sp. z o.o.Oddział w Warszawie, Warsaw
DermMedica Sp. z o.o., Wroclaw
Synexus Polska Sp. z o.o. Oddział we Wrocławiu, Wroclaw
Zaporizhzhya Regional Dermatology and Venereology Clinical Dispensary, Zaporizhzhya
Centrum Badań Klinicznych PI-House Sp. Z o.o., Gdansk
Alvotech Swiss AG
INDUSTRY